Advanced

Expression of the cytoskeleton linker protein ezrin in human cancers

Bruce, Benjamin; Khanna, Gaurav; Ren, Ling; Landberg, Göran LU ; Jirström, Karin LU ; Powell, Charles; Borczuk, Alain; Keller, Evan T.; Wojno, Kirk J. and Meltzer, Paul, et al. (2007) In Clinical and Experimental Metastasis 24(2). p.69-78
Abstract
Expression of the metastasis-associated protein, ezrin, in over 5,000 human cancers and normal tissues was analyzed using tissue microarray immunohistochemistry. Ezrin staining was compared between cancers and their corresponding normal tissues, between cancers of epithelial and mesenchymal origin, in the context of the putative inhibitor protein, merlin, and against clinicopathological data available for breast, lung, prostate cancers and sarcomas. Ezrin was found in most cancers and normal tissues at varying levels of intensity. In general ezrin was expressed at higher levels in sarcomas than in carcinomas. By normalizing the expression of ezrin in each cancer using ezrin expression found in the corresponding normal tissue, significant... (More)
Expression of the metastasis-associated protein, ezrin, in over 5,000 human cancers and normal tissues was analyzed using tissue microarray immunohistochemistry. Ezrin staining was compared between cancers and their corresponding normal tissues, between cancers of epithelial and mesenchymal origin, in the context of the putative inhibitor protein, merlin, and against clinicopathological data available for breast, lung, prostate cancers and sarcomas. Ezrin was found in most cancers and normal tissues at varying levels of intensity. In general ezrin was expressed at higher levels in sarcomas than in carcinomas. By normalizing the expression of ezrin in each cancer using ezrin expression found in the corresponding normal tissue, significant associations between ezrin were found in advancing histological grade in sarcomas (P = 0.02) and poor outcome in breast cancer (P = 0.025). Clinicopathologic associations were not changed by simultaneous assessment of ezrin and merlin in each patient sample for the cancer types examined. These data support a role for ezrin in the biology of human cancers and the need for additional studies in breast cancer and sarcoma patients that may validate ezrin as a marker of cancer progression and as a potential target for cancer therapy. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
tissue microarray, immunohistochemistry, ezrin, merlin, biomarker, prognosis
in
Clinical and Experimental Metastasis
volume
24
issue
2
pages
69 - 78
publisher
Springer
external identifiers
  • wos:000246103400001
  • scopus:34247603150
ISSN
1573-7276
DOI
10.1007/s10585-006-9050-x
language
English
LU publication?
yes
id
b0939ab7-6552-4b1a-a41c-ad5e4d3c1424 (old id 663153)
date added to LUP
2007-12-11 16:21:06
date last changed
2017-08-27 04:01:58
@article{b0939ab7-6552-4b1a-a41c-ad5e4d3c1424,
  abstract     = {Expression of the metastasis-associated protein, ezrin, in over 5,000 human cancers and normal tissues was analyzed using tissue microarray immunohistochemistry. Ezrin staining was compared between cancers and their corresponding normal tissues, between cancers of epithelial and mesenchymal origin, in the context of the putative inhibitor protein, merlin, and against clinicopathological data available for breast, lung, prostate cancers and sarcomas. Ezrin was found in most cancers and normal tissues at varying levels of intensity. In general ezrin was expressed at higher levels in sarcomas than in carcinomas. By normalizing the expression of ezrin in each cancer using ezrin expression found in the corresponding normal tissue, significant associations between ezrin were found in advancing histological grade in sarcomas (P = 0.02) and poor outcome in breast cancer (P = 0.025). Clinicopathologic associations were not changed by simultaneous assessment of ezrin and merlin in each patient sample for the cancer types examined. These data support a role for ezrin in the biology of human cancers and the need for additional studies in breast cancer and sarcoma patients that may validate ezrin as a marker of cancer progression and as a potential target for cancer therapy.},
  author       = {Bruce, Benjamin and Khanna, Gaurav and Ren, Ling and Landberg, Göran and Jirström, Karin and Powell, Charles and Borczuk, Alain and Keller, Evan T. and Wojno, Kirk J. and Meltzer, Paul and Baird, Kristin and McClatchey, Andrea and Bretscher, Anthony and Hewitt, Stephen M. and Khanna, Chand},
  issn         = {1573-7276},
  keyword      = {tissue microarray,immunohistochemistry,ezrin,merlin,biomarker,prognosis},
  language     = {eng},
  number       = {2},
  pages        = {69--78},
  publisher    = {Springer},
  series       = {Clinical and Experimental Metastasis},
  title        = {Expression of the cytoskeleton linker protein ezrin in human cancers},
  url          = {http://dx.doi.org/10.1007/s10585-006-9050-x},
  volume       = {24},
  year         = {2007},
}